Not applicableActive Not RecruitingNCT07556549
What this trial is testing
Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC
Who this might be right for
Non-Small Cell Lung Cancer ALK-positive
Pfizer 50